Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.

ABSTRACT: Background Atrial fibrillation (AF) is associated with increasing risk of thromboembolic or ischemic stroke. The CHA₂DS₂-VASc score is a well-established predictor of AF stroke. Patients with AF have an increased risk of stroke if they have diabetes. Use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) has been shown to be associated with favorable cardiovascular outcomes in patients with diabetes. It was unknown whether use of SGLT2i decreased stroke risk in patients with AF who have diabetes. Methods and Results A total of 9116 patients with AF and diabetes from the National Taiwan University historical cohort were longitudinally followed up for 5 years (January 2016-December 2020). The risk of stroke related to SGLT2i use was evaluated by Cox model, adjusting C

SUBMITTER: Chang SN 

PROVIDER: S-EPMC10227316 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature